Ergomed Gestion

Gestion contrôle des critères 0/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	no data
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	1.5yrs
Durée moyenne du mandat des membres du conseil d'administration	1.6yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Ergomed n'a pas de PDG, ou nous n'avons pas de données sur eux.

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Miroslav Reljanovic	Founder & Executive Chairman	5.9yrs	UK£964.30k	17.98% € 102.0m
Michael Spiteri	Chief Transformation & Technology Officer	less than a year	UK£52.77k	pas de données
Jonathan Curtain	CFO & Executive Director	less than a year	pas de données	pas de données
Michael Forstner	Head of Risk Management & Pharmacoepidemiology	5.1yrs	pas de données	pas de données
Sally Amanuel	President of PrimeVigilance	no data	pas de données	pas de données
Gordana Tonkovic	President of Clinical Research	no data	pas de données	pas de données
Ronel Steyn	Senior Vice President of Global Development	1.6yrs	pas de données	pas de données
Keith Byrne	Senior Vice-President of Capital Markets & Strategy	1.4yrs	pas de données	pas de données
Joanne Bletcher	Company Secretary	no data	pas de données	pas de données

1.5yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de 2EM n'est pas considérée comme expérimentée (ancienneté moyenne 1.5 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Miroslav Reljanovic	Founder & Executive Chairman	5.9yrs	UK£964.30k	17.98% € 102.0m
Jonathan Curtain	CFO & Executive Director	less than a year	pas de données	pas de données
Mark Enyedy	Independent Non-Executive Director	2yrs	UK£52.72k	pas de données
Llew Keltner	Independent Non-Executive Director	2.2yrs	UK£52.72k	pas de données
Anne Michelle Whitaker	Independent Non-Executive Director	less than a year	UK£27.89k	pas de données
John Dawson	Senior Independent Director	1.3yrs	UK£49.15k	pas de données

1.6yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 2EM ne sont pas considérés comme expérimentés (ancienneté moyenne 1.6 ans), ce qui suggère un nouveau conseil d'administration.

Ergomed Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Ergomed plc, Annual General Meeting, Jun 22, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Ergomed plc, Annual General Meeting, Jun 22, 2023

Full year 2022 earnings released: EPS: UK£0.30 (vs UK£0.26 in FY 2021)

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Now 21% undervalued after recent price drop

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Ergomed plc, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Now 21% undervalued

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Investor sentiment improved over the past week

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Investor sentiment improved over the past week

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Investor sentiment improved over the past week

Non-Executive Director has left the company

Investor sentiment improved over the past week

Full year 2020 earnings released

New 90-day high: €14.15

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: €13.40

New 90-day high: €12.10

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

New 90-day high: €9.76

New 90-day high: €9.58

New 90-day high - €7.68

New 90-day high - €6.86

Ergomed plc to Report First Half, 2020 Results on Sep 22, 2020

New 90-day high - €6.60

PDG

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen